Evaluation of Serum Adropin, Irisin, and Preptin Levels in Individuals with Benign Prostatic Hyperplasia and Prostate Cancer

Yıl 2025, Cilt: 4 Sayı: 4, 139 - 144, 30.12.2025

Solmaz Bodur , Nevin İlhan , Furkan Yildiz , Buket Berk

https://doi.org/10.59518/farabimedj.1775226

Öz

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are common urological conditions among aging men, characterized by benign enlargement and malignant progression of the prostate gland, respectively. This study was designed to answer the question of whether adropin, irisin, and preptin serum levels have an impact on the development of prostate disease in a total of 90 participants, including BPH (n=30), localized PCa (n=30), and healthy controls (n=30). The serum concentrations of these peptides were determined using enzyme-linked immunosorbent assay (ELISA). According to the findings, adropin and irisin levels were significantly lower in the BPH and PCa groups compared to the control group (p<0.001). Conversely, preptin levels were significantly higher in both the BPH and PCa groups compared to the control group (p<0.001), with preptin levels in the PCa group being higher than those in the BPH group (p<0.001). In conclusion, these findings highlight the complex interactions of these peptides in prostate pathophysiology, suggesting that adropin and irisin may be linked to metabolic dysregulation, while preptin is associated with cellular growth processes related to prostate malignancies. Furthermore, this study emphasizes the need for further studies to elucidate the specific roles and therapeutic potential of adropin, irisin and preptin in the management of prostate health and disease.

Anahtar Kelimeler

Adropin , BPH , Irisin , Preptin , Prostate health

Etik Beyan

This study was approved by the Fırat University Non-Interventional Research Ethics Committee under protocol number 2023/08-35. All participants were informed about the study objectives and procedures before participation. Written informed consent was obtained from all participants prior to inclusion in the study.

Benign Prostat Hiperplazisi ve Prostat Kanserli Bireylerde Serum Adropin, İrisin ve Preptin Düzeylerinin Değerlendirilmesi

Öz

Benign prostat hiperplazisi (BPH) ve prostat kanseri (PCa), yaşlanan erkekler arasında sık görülen ve sırasıyla prostat bezinin iyi huylu büyümesi ve kötü huylu gelişimi ile karakterize olan ürolojik durumlardır. Bu çalışma, BPH (n=30), lokalize PCa (n=30) ve sağlıklı kontrol grubundan (n=30) oluşan 90 katılımcıda adropin, irisin ve preptin serum düzeylerinin prostat hastalığı gelişiminde bir etkisi var mıdır sorusuna yanıt bulmak amacıyla tasarlanmıştır. Çalışmada bu peptidlerin serum konsantrasyonları, enzim bağlı immünosorbent test yöntemiyle ölçülmüştür. Elde edilen bulgulara göre BPH ve PCa gruplarında kontrol grubuna kıyasla adropin ve irisin düzeylerinde anlamlı bir azalma olduğu tespit edilmiştir (p<0.001). Buna karşılık, preptin düzeyleri BPH ve PCa gruplarında kontrol grubuna göre belirgin şekilde artmıştır (p<0.001) ve PCa grubunda preptin seviyeleri BPH grubundan daha yüksek bulunmuştur (p<0.001). Sonuç olarak elde edilen bu bulgular, prostat fizyopatolojisinde bu peptidlerin karmaşık etkileşimlerini ortaya koymakta, adropin ve irisin'in metabolik düzensizliklerle, preptin'in ise prostat maligniteleri ile ilişkili hücresel büyüme süreçleriyle bağlantılı olabileceğini düşündürmektedir. Bununla birlikte bu çalışma, adropin, irisin ve preptin'in prostat sağlığı ve hastalıklarının yönetimindeki spesifik rollerini ve terapötik potansiyellerini açıklamak için daha fazla çalışmaya ihtiyaç olduğunu vurgulamaktadır.

Anahtar Kelimeler

Adropin , BPH , İrisin , Preptin , Prostat sağlığı

Etik Beyan

Bu çalışma, Fırat Üniversitesi Girişimsel Olmayan Araştırmalar Etik Kurulu tarafından 2023/08-35 protokol numarasıyla onaylanmıştır. Tüm katılımcılar, çalışmaya katılmadan önce çalışma amaçları ve prosedürleri hakkında bilgilendirilmiştir. Çalışmaya dahil edilmeden önce tüm katılımcılardan yazılı bilgilendirilmiş onam alınmıştır.

Kaynakça

• Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia—what do we know? BJU Int. 2021;127(4):389-399.
• Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Lausanne). 2021;12:554078.
• Kania E, Janica M, Nesterowicz M, Modzelewski W, Cybulski M, Janica J. Advances and challenges in prostate cancer diagnosis: a comprehensive review. Cancers (Basel). 2025;17(13):2137.
• Bergengren O, Pekala KR, Matsoukas K, et al. 2022 update on prostate cancer epidemiology and risk factors—a systematic review. Eur Urol. 2023;84(2):191-206.
• Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as a fat-burning hormone with multiple functions—review of a decade of research. Molecules. 2020;25(3):549.
• Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options. Int J Urol. 2024;31(9):968-974.
• Chen L, Lu J, Hu J, Gong X. Unveiling the multifaceted role of adropin in various diseases (review). Int J Mol Med. 2024;54(4):90.
• Ungureanu MC, Bilha SC, Hogas M, Velicescu C, Leustean L, Teodoriu LC, Preda C. Preptin: a new bone metabolic parameter? Metabolites. 2023;13(9):991.
• Mrázková L, Lubos M, Voldřich J, et al. The final walk with preptin. PLoS One. 2024;19(9):e0309726.
• Nwabo Kamdje AH, Seke Etet PF, Kipanyula MJ, et al. Insulin-like growth factor-1 signaling in the tumor microenvironment: carcinogenesis, cancer drug resistance, and therapeutic potential. Front Endocrinol (Lausanne). 2022;13:927390.
• Paoletti I, Coccurello R. Irisin: a multifaceted hormone bridging exercise and disease pathophysiology. Int J Mol Sci. 2024;25(24):13480.
• Arhire LI, Mihalache L, Covasa M. Irisin: a hope in understanding and managing obesity and metabolic syndrome. Front Endocrinol (Lausanne). 2019;10:524.
• Alshanqiti KH, Alomar SF, Alzoman N, Almomen A. Irisin induces apoptosis in metastatic prostate cancer cells and inhibits tumor growth in vivo. Cancers (Basel). 2023;15(15):4000.
• Aslan R, Alp HH, Eryılmaz R, et al. Can irisin be a biomarker for prostate cancer? A case-control study. Asian Pac J Cancer Prev. 2020;21(2):505-509.
• Muhammed AA, Eid RMHM, Mohammed WS, Abdel-Fadeil MR. An association between adropin hormone and total testosterone in obese men: a case-control study. BMC Endocr Disord. 2022;22(1):192.
• Li N, Xie G, Zhou B, et al. Serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease. Front Physiol. 2021;12:696163.
• Gunaydin M, Aygun A, Usta M, Vural A, Ozsahin F. Serum adropin levels in patients with acute ischemic stroke. Medicine Science. 2019;8(3):698-702.
• Nergiz S, Altinkaya SO, Kurt Ömürlü İ, Yuksel H, Küçük M, Demircan Sezer S. Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol. 2015;31(9):730-735.
• Kıraç UI, Demir E, Ozkan H, et al. Maternal serum preptin levels in the pathogenesis and diagnosis of gestational diabetes mellitus. J Med Biochem. 2023;42(2):311-317.
• Li B, Li Y, Zhang T, et al. Preptin is a new predictor of coronary artery calcification. Clin Chim Acta. 2018;485:133-138.
• Mierzwicka A, Kuliczkowska-Plaksej J, Kolačkov K, Bolanowski M. Preptin in women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34(6):470-475.
• aeedi Sadr A, Ehteram H, Seyed Hosseini E, Alizadeh Zarei M, Hassani Bafrani H, Haddad Kashani H. The effect of irisin on proliferation, apoptosis, and expression of metastasis markers in prostate cancer cell lines. Oncol Ther. 2022;10(2):377-388.
• Provatopoulou X, Georgiou GP, Kalogera E, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15:898.
• Rabiee F, Lachinani L, Ghaedi S, Nasr-Esfahani MH, Megraw TL, Ghaedi K. New insights into the cellular activities of FNDC5/irisin and its signaling pathways. Cell Biosci. 2020;10:51.